Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
4
×
eli lilly
fda
indiana blog main
indiana top stories
novartis
avapritinib
blueprint medicines
boston
boulder/denver blog main
boulder/denver top stories
cancer
clinical trials
detroit blog main
detroit top stories
europe blog main
europe top stories
genentech
medullary thyroid cancer
national
new york blog main
new york top stories
non-small cell lung cancer
pralsetinib
raleigh-durham blog main
raleigh-durham top stories
roche
san diego blog main
san diego top stories
seattle blog main
seattle top stories
selpercatinib
texas blog main
What
fda
4
×
medicines
4
×
approval
drug
blueprint
cancer
new
ret
activity
address
amgen
approvals
approves
bio
biogen
candidate
candidates
carries
certain
clamped
class
covid
currently
delays
designed
developed
developing
economic
fast
genetic
gets
head
including
ipo
isn’t
latest
lot
marketing
migraine
muscle
Language
unset
Current search:
fda
×
medicines
×
" san francisco top stories "
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines